Go back to the Europarl portal

Choisissez la langue de votre document :

  • bg - български
  • es - español
  • cs - čeština
  • da - dansk
  • de - Deutsch
  • et - eesti keel
  • el - ελληνικά
  • en - English (Selected)
  • fr - français
  • ga - Gaeilge
  • hr - hrvatski
  • it - italiano
  • lv - latviešu valoda
  • lt - lietuvių kalba
  • hu - magyar
  • mt - Malti
  • nl - Nederlands
  • pl - polski
  • pt - português
  • ro - română
  • sk - slovenčina
  • sl - slovenščina
  • fi - suomi
  • sv - svenska
Parliamentary questions
18 April 2017
E-002776-17
Question for written answer
to the Commission
Rule 130
Dominique Bilde (ENF)

 Subject:  Tackling counterfeit medicines
 Answer(s) 

According to the WHO, a counterfeit medicine is ‘a medicine which is deliberately and fraudulently mislabelled with respect to identity and/or source’. Experts estimate that 10% of medicines in the world are counterfeits.

Counterfeit medicines are a danger to individual health and public health: they contribute to an increase in infection rates, deprive not only inventors and manufacturers but also governments of financial revenue, and are therefore an obstacle to further research.

1. What steps will the Commission take to tackle that trade more effectively?

2. Is the Commission considering launching a communication campaign in order to tackle the counterfeiting of medicines and reveal the dangers of that trade?

Original language of question: FR 
Last updated: 5 May 2017Legal notice